GT BIOPHARMA INC |
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 27/06 | GT Biopharma Says FDA Clears Investigational New Drug Application for Cancer Drug GTB-3650 | MT |
| 27/06 | GT Biopharma Shares Rise on FDA Clearance for Cancer-Drug Study | DJ |
Business Summary
The group has a portfolio of 3 products in clinical development phase (GTB-3550, GTB-3650 and GTB-5550; treatment of leukemia and solid tumors).
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Breen
CEO | Chief Executive Officer | 61 | 13/21/13 |
Jeffrey Miller
PRN | Corporate Officer/Principal | - | 14/22/14 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 78 | 01/23/01 | |
Bruce Wendel
BRD | Director/Board Member | 70 | 11/20/11 |
Rajesh Shrotriya
BRD | Director/Board Member | 79 | 13/21/13 |
Michael Breen
CEO | Chief Executive Officer | 61 | 13/21/13 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 0 | 96,230 | 0 | 0 | 89.34 % |
| Stock B | 1 | 2,156,651 | 2,012,830 ( 93.33 %) | 0 |
Company contact information
GT Biopharma, Inc.
8000 Marina Boulevard Suite 100
94005, Brisbane
+415 919 4040
http://www.gtbiopharma.com
Sector
| 1st Jan change | Capi. | |
|---|---|---|
| +55.32% | 815B | |
| +43.33% | 641B | |
| -6.75% | 352B | |
| +13.56% | 314B | |
| +10.68% | 303B | |
| +16.08% | 242B | |
| +2.17% | 224B | |
| +13.36% | 218B | |
| +8.48% | 168B |
- Stock Market
- Equities
- GTBP Stock
- Stock
- Company GT Biopharma Inc
